Dry Eye

Dry Eye is a prevalent and common disorder characterized by inflammation of the ocular surface and lacrimal glands and reductions in the quality and/or quantity of tears, causing discomfort, irritation, dryness, ocular fatigue and vision problems.
Learn More

~6.8% of the adult population (~16.4 million people)

Studies have shown the prevalence of DED in the United States is estimated at ~6.8% of the adult population (~16.4 million people) with prevalence increasing with age and higher in women.

Causes

  • Aging
  • Certain medical conditions including Sjogren’s syndrome, allergic eye disease, rheumatoid arthritis, lupus, etc.
  • Meibomian gland disorder
  • Certain medications, including antihistamines, decongestants, hormone replacement therapy, antidepressants, as well as medicines for high blood pressure, acne, birth control, and Parkinson’s disease
  • Corneal nerve desensitivity caused by contact lens use, nerve damage or surgery

Symptoms

  • Scratchy feeling, stinging or burning in eyes, red eyes, sensitivity to light
  • Blurry vision, sensation of having something in your eye, difficulty wearing contact lenses, difficulty with nighttime driving, watery eyes

Risk Factors

  • Age greater than 50
  • Female
  • Diet low in vitamin A or omega-3 fatty acids
  • Wearing contact lenses

Existing dry eye treatments and management consist of:

  • Prescription medications (eye drops such as Restasis, Xiidra, Miebo; nasal spray such as Tyrvaya)
  • Over-the-counter treatments (artificial tears such as Refresh, Systane)
  • Medical devices (punctal plugs)
  • Lifestyle and environmental changes

The dry eye market in the United States has been experiencing significant growth in recent years due to factors such as:

  • Aging population
  • Increased screen time
  • Greater awareness of the condition

Successful treatment of dry eye often requires a combination of treatments that target a patient’s specific symptoms and severity.

Many dry eye patients may be candidates for LACRIFILL® Canalicular Gel.